Semaglutide 2.4 mg Shows Promising Results in Reducing Liver Enzymes and Weight for MASH Patients

Promising Findings in the Treatment of MASH with Semaglutide 2.4 mg

At The Liver Meeting® 2026, Novo Nordisk unveiled significant findings from new real-world studies regarding the use of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in adults suffering from metabolic dysfunction-associated steatohepatitis (MASH). This novel treatment approach has generated interest due to its potential dual benefits: weight reduction and improvements in liver function.

Background on MASH

MASH is a progressive liver disease closely linked with metabolic dysfunction, obesity, and type 2 diabetes. It affects over 250 million people globally, with an alarming projection indicating a potential 160% increase in cases by 2030. Symptoms often remain undetected early on, complicating diagnosis and leading to severe health consequences if untreated, including the risk of liver cirrhosis and other complications.

The Study Overview

The findings presented originated from two key studies—PLATINUM-Truveta and RHODIUM-2. These observational and retrospective analyses reviewed the effects of semaglutide compared to conventional treatments like resmetirom in MASH patients. PLATINUM-Truveta involved over 2,800 individuals who initiated semaglutide treatment, measuring key markers like liver enzymes (AST and ALT), body weight, and HbA1c over three to six months.

The results were compelling. Patients receiving semaglutide experienced a substantial mean weight loss of 18.9 lb (approximately 8.6 kg), compared to only 5.6 lb (about 2.5 kg) in those treated with resmetirom after six months. Furthermore, the reductions in liver enzymes (AST and ALT) were markedly superior in the semaglutide group. For instance, AST levels dropped by 10.4 U/L in those on semaglutide versus 4.5 U/L in the other group. A similar trend was noted for ALT, where the semaglutide group saw a reduction of 14.8 U/L, while their counterparts showed a mere 11.6 U/L drop after the same period.

Long-Term Impacts

RHODIUM-2 extended the observation period, tracking 12-month outcomes between 2,479 individuals on semaglutide and over 70,000 who did not initiate the treatment. The findings further emphasized the ongoing benefits of semaglutide, with participants achieving significantly greater declines in liver enzyme levels and weight. Notably, the average reduction in body weight was recorded at 30.7 lb in the semaglutide group, compared to just 2.4 lb in those not on the treatment.

Moreover, significant improvements in HbA1c levels—an important indicator of blood sugar control—were also observed. The group receiving semaglutide experienced a reduction of 0.46 percentage points, highlighting the therapy’s potential advantages in managing diabetes alongside MASH.

Implications for Clinical Practice

Dr. Michelle Skinner Moore, Vice President of Medical Affairs at Novo, emphasized the clinical relevance of these findings, particularly in light of the challenges faced by those living with MASH. The disease often exhibits few symptoms, resulting in a delay in diagnosis and treatment. The data from PLATINUM-Truveta and RHODIUM provide vital insights, assisting healthcare professionals in making informed treatment decisions aimed at managing MASH effectively.

Moreover, Dr. Eric Lawitz, a prominent figure from the Texas Liver Institute, reiterated the significance of understanding each patient’s unique metabolic needs, further supporting the case for personalized treatment plans in managing MASH.

Future Directions

While these findings are promising, it’s important to approach the results with caution due to the retrospective nature of the studies. Future confirmatory trials are being planned to further establish the clinical benefits of semaglutide in this patient population.

In conclusion, semaglutide 2.4 mg presents an exciting potential as a treatment for adults afflicted with MASH. With its dual capacity to markedly reduce weight and improve liver health, this promising therapy could alter the treatment landscape for millions worldwide, paving the way for better management of this complex liver disease.